9809e7f25246ad67…

{
  "id": "NCT00093951",
  "type": "Study",
  "data": {
    "briefSummary": "The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.",
    "completionDate": "2007-09",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 280,
    "enrollmentType": null,
    "nctId": "NCT00093951",
    "phase": "PHASE2",
    "sponsorId": "saegis-pharmaceuticals",
    "startDate": "2004-04",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00093951"
  }
}